Growing collaboration with NYKHM

LONDON and NEW YORK, 3 June 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company, announces a collaboration with New York Kidney & Hypertension Medicine (NYKHM) to expand access to kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in patients with type 2 diabetes and chronic kidney disease stages 1-3b.

NYKHM is a national leader in applying EHR-integrated analytics and comprehensive, personalized treatment plans to manage chronic kidney disease in communities across Queens, Brooklyn, and the greater New York metropolitan area. The Renalytix-NYKHM collaboration will expand the use of kidneyintelX.dkd blood testing in underserved, high-risk communities to mitigate progressive decline in kidney function and help preserve patient health and quality of life. The program is expected to enable access to over 2,000 patients for kidneyintelX.dkd prognostic blood testing, complementing Renalytix expanded access programs throughout the Northeast region.

Enhanced insight into kidney function can help NYKHM physicians and their patients develop personalized treatment plans to reduce the risk of kidney, cardiovascular, and metabolic disease, further enabling long-term wellness. The kidneyintelX.dkd test is FDA-approved, reimbursed by Medicare, and recommended in international kidney disease clinical guidelines.

As part of the collaboration, Renalytix and NYKHM will also engage in:

• Community-Based Provider Education: Coordinating joint educational sessions for primary care physicians to promote early-stage CKD detection and risk stratification.
• Patient Awareness Initiatives: Launching a public-facing campaign to educate patients about kidney disease risk factors and the importance of proactive management.
• Premila Bhat, Partner, NYKHM and Managing Partner, Tidal Dialysis, LLC, said: "We are dedicated to bringing the latest medical innovations to our communities to ensure that our patients with chronic kidney disease can take charge of their health and wellness. The kidneyintelX.dkd test enables both physicians and patients to understand kidney disease risk early, so we can take timely action and deliver the most effective care available today."

James McCullough, CEO of Renalytix, commented: "Dr. Bhat and her team represent exactly the type of forward-thinking, patient-centered partners with whom we want to align. This partnership is a clear demonstration of how early prognosis, combined with community-based care, can shift the paradigm toward earlier detection and better outcomes in kidney disease."